Skip to main content
OpenTrials
Completed

NCT Number: NCT04370613

Imagery Vividness and Arousal Responses to Prospective Imagery

Research has shown that mental imagery appears to carry emotion better than verbal communication. One way this can be noted is that emotional mental imagery trigger physiological arousal responses. These may be important for treatment techniques using mental imagery, such as imaginal exposure and imagery re-scripting. However, as the development of clinical applications increasingly considers the use of flashpoint imagery, i.e. mental imagery of short duration, it is of interest to examine whether also flashpoint imagery trigger arousal responses. This study examines the arousal response to flashpoint imagery of different valence (positive, negative, and neutral).

Moreover, emerging evidence suggest that depressed individuals find it more difficult to produce mental imagery of positive future events (less accessible and vivid) than healthy controls. In addition, individuals with clinical anxiety appear to be able to produce imagery of negative future events more easily than healthy controls. This study explores whether these results can be noted also in sub-clinical symptoms of depression and anxiety, and if so, if they are accompanied with corresponding changes in arousal responses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Uppsala University, Department of Psychology

Uppsala, Sweden

About this study

This study takes part in a single session. Participants will produce flashpoint imagery of future events while skin conductance responses, imagery vividness ratings, valence and arousal ratings are collected. Participants will also fill in questionnaires on depression and anxiety symptoms, as well as a questionnaire measuring general propensity for mental imagery.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or over
  • Fluent in Swedish
  • Willing and able to provide informed consent and complete study procedures

Exclusion criteria

  • Current psychiatric disorder
  • Current use of psychotropic medication

Treatment and study plan

Prospective Imagery visualization task

Behavioral

Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).

Primary outcomes

  1. Imagery vividness ratings

    Time frame: Day 1

    Scale: 1-5; no image at all - image as clear and vivd as real life

  2. Skin conductance response (SCR)

    Time frame: Day 1

    SCR is used to measure physiological arousal response to the mental imagery production. The study evaluates differences in SCR between valences of prospective imagery (neutral, negative, positive) and possible covariation with self-rated anxiety or depression symptoms.

Secondary outcomes

  1. Time in seconds it takes to construct a situation to visualize

    Time frame: Day 1

    Measured as the time period from the presentation of the instruction until the participant reports a constructed situation.

  2. Subjective Valence Ratings

    Time frame: Day 1

    Subjective Valence Ratings for each produced mental imagery (0-100; negative to positive)

  3. Subjective Arousal Ratings

    Time frame: Day 1

    Subjective Arousal Ratings for each produced mental imagery (0-100; 0=no arousal, 100=maximum arousal)

  4. The Vividness of Visual Imagery Questionnaire

    Time frame: Day 1

    This is a self-rated questionnaire measuring vividness of visual mental imagery. Higher scores indicate higher level of vividness (range 0-80)

  5. State-Trait Anxiety Inventory

    Time frame: Day 1

    This is a self-rated questionnaire measuring trait anxiety. Higher scores indicate higher level of trait anxiety (range 20-80)

  6. Formulär för patienthälsa (PHQ-9)

    Time frame: Day 1

    This is a self-rated questionnaire for measuring depression symptoms. Higher scores indicate more symptoms of depression (range 0-27 + specific question of how disabling the symptoms are)

Sponsors and collaborators

Lead sponsor

Uppsala University

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 1, 2020
Registry last updated
Oct 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.